JP2024539370A5 - - Google Patents

Info

Publication number
JP2024539370A5
JP2024539370A5 JP2024525930A JP2024525930A JP2024539370A5 JP 2024539370 A5 JP2024539370 A5 JP 2024539370A5 JP 2024525930 A JP2024525930 A JP 2024525930A JP 2024525930 A JP2024525930 A JP 2024525930A JP 2024539370 A5 JP2024539370 A5 JP 2024539370A5
Authority
JP
Japan
Prior art keywords
biomarkers
individual
cells
cbmcs
tlr4 agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024525930A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024539370A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2022/051283 external-priority patent/WO2023070153A1/en
Publication of JP2024539370A publication Critical patent/JP2024539370A/ja
Publication of JP2024539370A5 publication Critical patent/JP2024539370A5/ja
Pending legal-status Critical Current

Links

JP2024525930A 2021-10-26 2022-10-26 呼吸器感染リスクを決定するための方法 Pending JP2024539370A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2021903424A AU2021903424A0 (en) 2021-10-26 Methods for determining respiratory infection risk
AU2021903424 2021-10-26
PCT/AU2022/051283 WO2023070153A1 (en) 2021-10-26 2022-10-26 Methods for determining respiratory infection risk

Publications (2)

Publication Number Publication Date
JP2024539370A JP2024539370A (ja) 2024-10-28
JP2024539370A5 true JP2024539370A5 (enExample) 2025-11-14

Family

ID=86160222

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024525930A Pending JP2024539370A (ja) 2021-10-26 2022-10-26 呼吸器感染リスクを決定するための方法

Country Status (8)

Country Link
US (1) US20240418708A1 (enExample)
EP (1) EP4423299A1 (enExample)
JP (1) JP2024539370A (enExample)
KR (1) KR20240093511A (enExample)
CN (1) CN118159668A (enExample)
AU (1) AU2022375204A1 (enExample)
CA (1) CA3233202A1 (enExample)
WO (1) WO2023070153A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121075427A (zh) * 2025-08-14 2025-12-05 中山大学·深圳 用于急性上呼吸道感染易感性的预测标志物及预测方法

Similar Documents

Publication Publication Date Title
Marzi et al. Single dose of a VSV-based vaccine rapidly protects macaques from Marburg virus disease
Roux et al. Brucella requires a functional Type IV secretion system to elicit innate immune responses in mice
US20230045305A1 (en) Rna determinants for distinguishing between bacterial and viral infections
Esposito et al. Toll-like receptor 3 gene polymorphisms and severity of pandemic A/H1N1/2009 influenza in otherwise healthy children
Weinberger et al. Impaired immune response to primary but not to booster vaccination against hepatitis B in older adults
US20110105343A1 (en) Systems Biology Approach Predicts Immunogenicity of Vaccines
TW201131032A (en) Blood transcriptional signature of active versus latent mycobacterium tuberculosis infection
CN107001455A (zh) 利用hnl的诊断方法
AU2007327995A1 (en) Interferon alpha-induced pharmacodynamic markers
Øvstebø et al. Identification of genes particularly sensitive to lipopolysaccharide (LPS) in human monocytes induced by wild-type versus LPS-deficient Neisseria meningitidis strains
Duffy Understanding immune variation for improved translational medicine
US20230241105A1 (en) Methods of use of allergen-specific t cells in allergy and asthma
Yi et al. Transcriptional profiling of human peripheral blood mononuclear cells stimulated by mycobacterium tuberculosis PPE57 identifies characteristic genes associated with type I interferon signaling
JP2024539370A5 (enExample)
JP2023532444A5 (enExample)
Massilamany et al. SJL mice infected with Acanthamoeba castellanii develop central nervous system autoimmunity through the generation of cross-reactive T cells for myelin antigens
Pisanic et al. Early, robust mucosal secretory IgA but not IgG response to SARS-CoV-2 spike in oral fluid is associated with faster viral clearance and COVID-19 symptom resolution
JP2023516745A5 (enExample)
CN116994646B (zh) 一种菌阳活动性肺结核风险评估模型的构建方法与应用
Castillo et al. Diagnosis and management of infectious complications of childhood rheumatic diseases
Forčić et al. Detection and characterization of measles virus strains in cases of subacute sclerosing panencephalitis in Croatia
US20230417747A1 (en) Methods and compositions for diagnosing and treating virally-associated disease
Fujino et al. Loop-mediated isothermal amplification (LAMP) aids the clinical diagnosis of pertussis
US20240418708A1 (en) Methods for determining respiratory infection risk
Bartholomeus et al. Transcriptomic profiling of different responder types in adults after a Priorix® vaccination